Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00803062 · OUTCOME

Overall Survival

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From entry into the study to death or the date of last contact, assessed up to 5 years

What was measured

The observed length of life from randomization into the study to death or the date of last contact.

Analysis population: All randomized patients.

Groups in this outcome

Arm I (Paclitaxel and Cisplatin)

Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity

Arm II (Paclitaxel, Cisplatin, Bevacizumab)

Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity

Arm III (Topotecan Hydrochloride and Paclitaxel)

Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity

Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)

Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Paclitaxel and Cisplatin)114
Arm II (Paclitaxel, Cisplatin, Bevacizumab)115
Arm III (Topotecan Hydrochloride and Paclitaxel)111
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)112

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Paclitaxel and Cisplatin)14.26Not reported10.8316.82Not reported
Arm II (Paclitaxel, Cisplatin, Bevacizumab)17.51Not reported13.9622.93Not reported
Arm III (Topotecan Hydrochloride and Paclitaxel)12.68Not reported10.1515.90Not reported
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)16.20Not reported12.7118.96Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10.83
        upper Limit
        16.82
        value
        14.26
      2. group Id
        OG001
        lower Limit
        13.96
        upper Limit
        22.93
        value
        17.51
      3. group Id
        OG002
        lower Limit
        10.15
        upper Limit
        15.90
        value
        12.68
      4. group Id
        OG003
        lower Limit
        12.71
        upper Limit
        18.96
        value
        16.20
denoms
  1. counts
    1. group Id
      OG000
      value
      114
    2. group Id
      OG001
      value
      115
    3. group Id
      OG002
      value
      111
    4. group Id
      OG003
      value
      112
    units
    Participants
description
The observed length of life from randomization into the study to death or the date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity
    id
    OG000
    title
    Arm I (Paclitaxel and Cisplatin)
  2. description
    Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity
    id
    OG001
    title
    Arm II (Paclitaxel, Cisplatin, Bevacizumab)
  3. description
    Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity
    id
    OG002
    title
    Arm III (Topotecan Hydrochloride and Paclitaxel)
  4. description
    Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity
    id
    OG003
    title
    Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)
param Type
MEDIAN
population Description
All randomized patients.
reporting Status
POSTED
time Frame
From entry into the study to death or the date of last contact, assessed up to 5 years
title
Overall Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice